chlorambucil has been researched along with abt-199 in 13 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (15.38) | 24.3611 |
| 2020's | 11 (84.62) | 2.80 |
| Authors | Studies |
|---|---|
| Al-Sawaf, O; Bahlo, J; Boettcher, S; Dixon, M; Eichhorst, B; Fink, AM; Fischer, K; Fogliatto, LM; Goede, V; Hallek, M; Humerickhouse, R; Humphrey, K; Kipps, TJ; Kreuzer, KA; Langerak, AW; Le Dû, K; Liberati, AM; Mobasher, M; Niemann, CU; Opat, S; Pinilla-Ibarz, J; Ritgen, M; Robinson, S; Robrecht, S; Samoylova, O; Sivcheva, L; Stilgenbauer, S; Tandon, M; Tausch, E; Warburton, S; Weinkove, R; Wendtner, CM | 1 |
| Andreadis, C; Fakhri, B | 1 |
| Al-Sawaf, O; Bahlo, J; Bloehdorn, J; Bullinger, L; Döhner, H; Dolnik, A; Eichhorst, B; Fink, AM; Fischer, K; Hallek, M; Humphrey, K; Jiang, Y; Kneba, M; Kreuzer, KA; Lurà, MP; Mertens, D; Ritgen, M; Robrecht, S; Schary, W; Schneider, C; Stilgenbauer, S; Tandon, M; Tausch, E; Zhang, C | 1 |
| Gao, A; Gao, W; Huo, D; Ran, X; Sheng, Z; Song, S; Yu, M; Zhu, H | 1 |
| Seymour, JF | 1 |
| Al-Sawaf, O; Eichhorst, B; Fink, AM; Fischer, K; Fogliatto, LM; Hallek, M; Kipps, TJ; Kreuzer, KA; Le Dû, K; Liberati, AM; Niemann, CU; Opat, S; Pinilla-Ibarz, J; Ritgen, M; Robinson, S; Robrecht, S; Samoylova, O; Schary, W; Sinha, A; Sivcheva, L; Stilgenbauer, S; Tandon, M; Tausch, E; Weinkove, R; Wendtner, CM; Zhang, C | 1 |
| De la Serna-Torroba, J; Escudero-Vilaplana, V; Hernández-Rivas, JÁ; Moreno-Martínez, E; Sánchez-Cuervo, M; Sánchez-Hernández, R | 1 |
| Messori, A | 1 |
| Do, N; Thielen, FW | 1 |
| Al-Sawaf, O; Balasubramanian, S; Chang, YM; Choi, Y; Chyla, B; Eichhorst, B; Fink, AM; Fischer, K; Frenzel, LP; Hallek, M; Jiang, Y; Jin, HY; Kotak, A; Kreuzer, KA; Pallasch, CP; Paulson, JN; Peifer, M; Ritgen, M; Robrecht, S; Schneider, C; Stilgenbauer, S; Tausch, E; Zhang, C | 1 |
| Romero, D | 1 |
| Baeten, K; Benjamini, O; Caces, DB; Follows, G; Howes, A; Janssens, A; Kater, AP; Levin, MD; Moreno, C; Munir, T; Niemann, CU; Osterborg, A; Owen, C; Parisi, L; Qi, K; Qi, Q; Robak, T; Schuier, N; Simkovic, M; Srinivasan, S; Stevens, D; Voloshin, S; Vorobyev, V; Yagci, M; Ysebaert, L | 1 |
| Baeten, K; Benjamini, O; Caces, DB; Follows, GA; Howes, A; Janssens, A; Kater, AP; Levin, MD; Moreno, C; Munir, T; Niemann, CU; Owen, C; Parisi, L; Qi, K; Qi, Q; Robak, T; Schuier, N; Simkovic, M; Sinet, P; Srinivasan, S; Voloshin, S; Vorobyev, V; Yagci, M; Ysebaert, L | 1 |
1 review(s) available for chlorambucil and abt-199
| Article | Year |
|---|---|
Comparison of acalabrutinib plus obinutuzumab, ibrutinib plus obinutuzumab and venetoclax plus obinutuzumab for untreated CLL: a network meta-analysis.
Topics: Adenine; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Bridged Bicyclo Compounds, Heterocyclic; Chlorambucil; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Network Meta-Analysis; Piperidines; Prospective Studies; Pyrazines; Sulfonamides | 2020 |
3 trial(s) available for chlorambucil and abt-199
| Article | Year |
|---|---|
Venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab for previously untreated chronic lymphocytic leukaemia (CLL14): follow-up results from a multicentre, open-label, randomised, phase 3 trial.
Topics: Adolescent; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bridged Bicyclo Compounds, Heterocyclic; Chlorambucil; Female; Follow-Up Studies; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Progression-Free Survival; Sulfonamides; Treatment Outcome | 2020 |
Transcriptomic profiles and 5-year results from the randomized CLL14 study of venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab in chronic lymphocytic leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bridged Bicyclo Compounds, Heterocyclic; Chlorambucil; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Transcriptome | 2023 |
Fixed-duration ibrutinib-venetoclax versus chlorambucil-obinutuzumab in previously untreated chronic lymphocytic leukaemia (GLOW): 4-year follow-up from a multicentre, open-label, randomised, phase 3 trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chlorambucil; Female; Follow-Up Studies; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Pneumonia | 2023 |
9 other study(ies) available for chlorambucil and abt-199
| Article | Year |
|---|---|
Venetoclax and Obinutuzumab in Patients with CLL and Coexisting Conditions.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Bridged Bicyclo Compounds, Heterocyclic; Chlorambucil; Comorbidity; Female; Humans; Kaplan-Meier Estimate; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Progression-Free Survival; Sulfonamides | 2019 |
CLL14 Trial: Fixed-Duration Chemotherapy-Free Regimen for Frail Patients with Treatment-Naïve CLL.
Topics: Adenine; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bridged Bicyclo Compounds, Heterocyclic; Chlorambucil; Clinical Trials, Phase III as Topic; Frail Elderly; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Pyrazoles; Pyrimidines; Sulfonamides; Survival Rate; Treatment Outcome | 2019 |
Prognostic and predictive impact of genetic markers in patients with CLL treated with obinutuzumab and venetoclax.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bridged Bicyclo Compounds, Heterocyclic; Chlorambucil; Chromosome Aberrations; Clinical Trials, Phase III as Topic; Follow-Up Studies; Genes, Neoplasm; Genetic Markers; Humans; Immunoglobulin Heavy Chains; Immunoglobulin Variable Region; Kaplan-Meier Estimate; Leukemia, Lymphocytic, Chronic, B-Cell; Multicenter Studies as Topic; Mutation; Neoplasm, Residual; Prognosis; Progression-Free Survival; Remission Induction; Sulfonamides | 2020 |
Venetoclax plus obinutuzumab therapy for front-line treatment of chronic lymphocytic leukaemia.
Topics: Antibodies, Monoclonal, Humanized; Bridged Bicyclo Compounds, Heterocyclic; Chlorambucil; Follow-Up Studies; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Sulfonamides | 2020 |
Cost-utility analysis of venetoclax in combination with obinutuzumab as first-line treatment of chronic lymphocytic leukaemia in Spain.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Bridged Bicyclo Compounds, Heterocyclic; Chlorambucil; Cost-Benefit Analysis; Cyclophosphamide; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Quality of Life; Rituximab; Spain; Sulfonamides | 2022 |
Long-term progression-free survival in patients with chronic lymphocytic leukemia treated with novel agents: An analysis based on indirect comparisons.
Topics: Antineoplastic Combined Chemotherapy Protocols; Artificial Intelligence; Chlorambucil; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Progression-Free Survival; Rituximab | 2023 |
Cost-Effectiveness of Venetoclax Plus Obinutuzumab Versus Chlorambucil Plus Obinutuzumab for the First-Line Treatment of Adult Patients With Chronic Lymphocytic Leukemia: An Extended Societal View.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Chlorambucil; Cost-Benefit Analysis; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Quality-Adjusted Life Years | 2023 |
Venetoclax-obinutuzumab combinations are effective in fit patients with CLL.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Chlorambucil; Humans; Leukemia, Lymphocytic, Chronic, B-Cell | 2023 |
Impact of Minimal Residual Disease on Progression-Free Survival Outcomes After Fixed-Duration Ibrutinib-Venetoclax Versus Chlorambucil-Obinutuzumab in the GLOW Study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bridged Bicyclo Compounds, Heterocyclic; Chlorambucil; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Neoplasm, Residual; Progression-Free Survival | 2023 |